Suppr超能文献

三种不同抗血小板药物联合应用对全血中血小板和白细胞的体外作用。

Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.

作者信息

Zhao L, Bath P, Heptinstall S

机构信息

Centre for Vascular Research, University of Nottingham, Nottingham NG5 1PB.

出版信息

Br J Pharmacol. 2001 Sep;134(2):353-8. doi: 10.1038/sj.bjp.0704248.

Abstract
  1. Antiplatelet drugs have been demonstrated to reduce the incidence of recurrent events in patients with symptomatic vascular disease. However, there is no experimental data indicating the effects of these agents when given together on platelets and leukocytes. We investigated the ability of aspirin (an inhibitor of cyclo-oxygenase), dipyridamole (an inhibitor of phospodiesterases and adenosine uptake) and AR-C69931 (a direct acting P(2T) antagonist with effects similar to those of clopidogrel which can be used in vitro) when used alone or in combination to inhibit platelet and leukocyte function. 2. Measurements of platelet and leukocyte function were performed in blood taken from normal volunteers, and the inhibitory effects of aspirin (100 micromol l(-1)), dipyridamole (10 micromol l(-1)) and AR-C66931 (100 nmol l(-1)) were determined. Platelet aggregation was induced by stirring blood with and without adenosine diphosphate (ADP) or platelet activating factor (PAF) and measured by platelet counting. Platelet P-selectin expression, platelet-leukocyte conjugate formation, and leukocyte activation were determined by flow cytometry. 3. Dipyridamole, AR-C69931, dipyridamole and AR-C69931, dipyridamole and aspirin, AR-C69931 and aspirin, and all three agents together inhibited platelet aggregation induced by stirring, ADP and PAF (P<0.01). However, it was only the combination of all three agents inhibited P-selectin expression (P<0.01). Similarly, it was the combination of all three antiplatelet agents that most consistently inhibited platelet-monocyte and platelet-neutrophil conjugate formation and monocyte and neutrophil activation. 4. Since both platelets and leukocytes are thought to contribute to arterial thrombosis and atherosclerosis, it is possible that combinations of different antiplatelet agents with different mechanisms of action may afford better protection than individual or pairs of agents used on their own.
摘要
  1. 抗血小板药物已被证明可降低有症状血管疾病患者复发事件的发生率。然而,尚无实验数据表明这些药物联合使用时对血小板和白细胞的影响。我们研究了阿司匹林(一种环氧化酶抑制剂)、双嘧达莫(一种磷酸二酯酶和腺苷摄取抑制剂)和AR-C69931(一种直接作用的P(2T)拮抗剂,其作用类似于氯吡格雷,可用于体外实验)单独使用或联合使用时抑制血小板和白细胞功能的能力。2. 在取自正常志愿者的血液中进行血小板和白细胞功能的检测,并测定阿司匹林(100微摩尔/升)、双嘧达莫(10微摩尔/升)和AR-C66931(100纳摩尔/升)的抑制作用。通过在有或无二磷酸腺苷(ADP)或血小板活化因子(PAF)的情况下搅拌血液诱导血小板聚集,并通过血小板计数进行测量。通过流式细胞术测定血小板P-选择素表达、血小板-白细胞共轭物形成和白细胞活化。3. 双嘧达莫、AR-C69931、双嘧达莫与AR-C69931联合、双嘧达莫与阿司匹林联合、AR-C69931与阿司匹林联合以及三种药物共同使用均抑制了搅拌、ADP和PAF诱导的血小板聚集(P<0.01)。然而,只有三种药物联合使用才能抑制P-选择素表达(P<0.01)。同样,正是三种抗血小板药物联合使用最持续地抑制了血小板-单核细胞和血小板-中性粒细胞共轭物形成以及单核细胞和中性粒细胞活化。4. 由于血小板和白细胞均被认为与动脉血栓形成和动脉粥样硬化有关,不同作用机制的抗血小板药物联合使用可能比单独使用一种药物或两种药物联合使用提供更好的保护。

相似文献

引用本文的文献

4
Improving the Quality of EDTA-treated Blood Specimens from Mice.提高 EDTA 处理的小鼠血液标本的质量。
J Am Assoc Lab Anim Sci. 2022 Mar 1;61(2):188-194. doi: 10.30802/AALAS-JAALAS-21-000093. Epub 2022 Jan 12.
5
A meta-analysis on anticoagulation after vascular trauma.一项关于血管创伤后抗凝治疗的荟萃分析。
Eur J Trauma Emerg Surg. 2020 Dec;46(6):1291-1299. doi: 10.1007/s00068-020-01321-4. Epub 2020 Feb 17.

本文引用的文献

3
Combination therapy with clopidogrel and aspirin after coronary stenting.冠状动脉支架置入术后氯吡格雷与阿司匹林联合治疗。
Catheter Cardiovasc Interv. 2000 Jul;50(3):276-9. doi: 10.1002/1522-726x(200007)50:3<276::aid-ccd2>3.0.co;2-p.
8
Platelets and stroke.血小板与中风。
Vasc Med. 1999;4(3):165-72. doi: 10.1177/1358836X9900400307.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验